VIENNA — The highly selective oral Janus kinase (JAK) inhibitor SHR0302 (ivarmacitinib) enables more patients with active rheumatoid arthritis to meet American College of Rheumatology (ACR) response ...
Oral upadacitinib combined with topical ruxolitinib cream may be a promising therapeutic approach for patients with progressive nonsegmental vitiligo.
The Food and Drug Administration on Jan. 14 approved two oral JAK-1 inhibitors for patients with moderate-to-severe atopic dermatitis (AD) — upadacitinib and abrocitinib — making them the first oral ...
Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW ORLEANS -- ...
DUBLIN--(BUSINESS WIRE)--The "Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering. The report ...
Deficiency of ubiquitin-specific peptidase 18 (USP18) is a severe type I interferonopathy. USP18 down-regulates type I interferon signaling by blocking the access of Janus-associated kinase 1 (JAK1) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback